-
Rurioctocog alfa pegol for preventive treatment of hemophilia A: results of phase III PROPEL study
Time of Update: 2021-04-23
The FVIII drug Rurioctocog alfa pegol has been proven to be effective in the preventive treatment of PwHA when the lowest level is ≥1%, and its safety is controllable.
-
Bayer's Copanlisib freeze-dried preparation for injection is included in the priority review program
Time of Update: 2021-04-23
At the recently opened 2021AACR virtual conference, Bayer announced the results of a phase III clinical trial of Copanlisib and Rituximab in the treatment of relapsed indolent non-Hodgkin's lymphoma (iNHL).
-
How to identify and treat acquired coagulation factor deficiency based on the "four coagulation factors"
Time of Update: 2021-04-23
This article summarizes the classification and diagnosis and treatment of acquired inhibitors of anticoagulation factors (autoantibodies) in the coagulation cascade, and aims to provide references for clinicians to identify and treat acquired coagulation factor deficiency in clinical work.
-
Lancet: Supports the use of platelet function or genetic testing to optimize drug choices for PCI patients
Time of Update: 2021-04-22
Compared with the standard clopidogrel prevention program, selection of antiplatelet therapy based on the characteristics of hepatic cytochrome p4502c19 gene after PCI can improve the efficacy, improve safety, and reduce the risk of minor bleeding.
-
4.17 World Tumor Day Lymphoma Cases | The small inconspicuous lump on the baby's neck, grow up a little bit, parents must pay attention!
Time of Update: 2021-04-22
On November 24, 2020, a popular science article on the WeChat public account of the Second Affiliated Hospital of Xi'an Jiaotong University, "Is it a bad disease for a child to have a "small bump" on the neck?" "Aroused the attention of parents, and everyone discussed it in the comment section.
-
The current status of renal anemia treatment is still not ideal, and innovative solutions are urgently needed in clinical practice
Time of Update: 2021-04-22
Intravenous iron can raise hemoglobin levels faster, quickly meet the needs of patients, and Reducing the amount of blood transfusion has shown therapeutic advantages in the treatment of renal anemia.
-
The full course of intensive treatment suitable for transplanted MM patients may be extended to 70 years old
Time of Update: 2021-04-21
Although previous studies have shown that age alone cannot be used as a limiting factor for ASCT, whether this full-course intensive treatment strategy can be extended to 70 years old in patients with good physical status and organ function, there is currently a lack of prospective randomized research data .
-
Professor Qiu Lugui: Diagnosis and treatment of T-cell chronic lymphoproliferative diseases | The 4th China Chronic Lymphocytic Leukemia Conference
Time of Update: 2021-04-20
According to the 2016 WHO classification of mature T-cell lymphoma, it is mainly divided into nodular, extranodal, skin-based and leukemia type 4 In the big category, Professor Qiu mainly introduced the diagnosis and treatment of T-lymphocytic leukemia (T-PLL) and large granular lymphocytic leukemia (LGLL) in the leukemia type.
-
Inventory: Current status and future direction of third-line treatment for chronic myeloid leukemia
Time of Update: 2021-04-19
Current status of third-line CML treatment: Resistance: 15%-20% of second-line drugs due to resistance during first-line imatinib treatment for 5 years [1], second-line treatment has a higher resistance rate, 60%-70% of patients Major molecular remission (MMR) and complete cytogenetic remission (CCyR) cannot be achieved after two years of treatment [2].
-
The world's first BCMA targeted CAR-T therapy was approved for marketing!
Time of Update: 2021-04-19
This is the second CAR-T cell therapy brought by the company after BMS brought the company’s first and fourth CAR-T therapy Breyanzi last month, and the first targeted B cell maturation approved by the FDA Antigen (BCMA) CAR-T cell therapy.
-
Professor Yi Shuhua: Diagnosis and Treatment of Lymphoma in the Marginal Zone of the Spleen|The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-04-19
A study of long-term follow-up data of 1298 SMZL patients showed that the 5-year overall survival (OS) rate of SMZL patients was as high as 67.
New progress in SMZL treatment Professor Yi Shuhua emphasized that some SMZL patients have no clinical symptoms.
-
Professor Fan Lei: Diagnosis and Treatment of Mantle Cell Lymphoma|The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-04-19
The results of the study showed that the R-BAC chemotherapy regimen (rituximab, bendamustine, cytarabine) achieved 83% ORR, CR rate 60%, and PFS in MCL patients after BTK inhibitor treatment failed.
-
Deqi Pharmaceuticals PAK4/NAMPT dual target inhibitor ATG-019 clinical trial application approved in China
Time of Update: 2021-04-19
In the future, I look forward to the launch of the first clinical trial of ATG-019 in mainland China, which will bring a new treatment option for patients with advanced solid tumors and non-Hodgkin's lymphoma.
-
Prof. Dehui Zou: Treatment progress and future prospects of B-cell lymphoma
Time of Update: 2021-04-19
Professor Zou Dehui In recent years, Chimeric Antigen Receptor (CAR) T-cell therapy has brought revolutionary progress in the treatment of lymphoma.
For patients with relapsed/refractory DLBCL (especially those who have received ≥2 line treatment in the past), CAR-T cell therapy is currently a more effective treatment method, which can significantly improve the efficacy compared with traditional salvage treatments.
-
FDA Update | Approves isatuximab-irfc to treat patients with multiple myeloma
Time of Update: 2021-04-19
The IKEMA study (NCT03275285) is a multi-country, multi-center, randomized, open-label, dual-arm, phase 3 study that evaluated isatuximab-irfc combined with carfilzomib and dexamethasone in RRMM patients who have previously received 1-3 lines of treatment The efficacy and safety.
-
Professor Yi Shuhua: First-line treatment options for CLL | The 4th China Chronic Lymphocytic Leukemia Conference
Time of Update: 2021-04-19
In addition, for young Fit CLL patients, data from multiple clinical trials have shown that fludarabine, cyclophosphamide combined with rituximab (FCR) regimen or bendamustine + rituximab (BR) regimen are all treated It has a significant curative effect, with an effective rate of over 90%, and a 5-year median PFS rate of about 50 months.
-
Professor Yang Shenmiao: Research progress in the treatment of relapsed and refractory CLL|The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-04-19
Professor Yang Shenmiao also pointed out that the domestic BTK inhibitor Zebutinib also showed good efficacy in relapsed and refractory CLL, and looked forward to the announcement of the results after the extended follow-up time of related studies.
-
Professor Qian Zhengzi: Current status and prospects of treatment of Hodgkin's lymphoma in the era of new drugs
Time of Update: 2021-04-19
The results of the study announced at the 2019 ASH Conference showed that the complete metabolic remission (CMR) rate of second-line patients with relapsed and refractory HL after receiving BV combined with ICE salvage chemotherapy can reach 69.
-
ADC drugs targeting CD22 are effective in children with R/R ALL
Time of Update: 2021-04-19
Recently, Professor Erica Brivio and others reported the results of a phase I clinical study (ITCC-059 trial) on the efficacy and safety of CD22-targeted ADC drug IO in the treatment of CD22+ children with R/R ALL.
-
Blood | Zhang Haojian's team reveals the molecular mechanism of RNA binding protein YBX1 in acute myeloid leukemia
Time of Update: 2021-04-19
The study found that the RNA binding protein YBX1 regulates the survival of myeloid leukemia cells and is essential for the occurrence and development of AML, but does not affect normal hematopoietic and hematopoietic stem cell functions.
